Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis.

In conclusion, modified VRD-lite had similar efficacy with, but better tolerability than, twVRD in transplant-eligible patients. PMID: 31673952 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31673952?dopt=Abstract

Source: International Journal of Hematology - October 29, 2019 Category: Hematology Authors: Suzuki K, Tsukada N, Nishimura N, Nagata Y, Okazuka K, Mishima Y, Yokoyama M, Nishiwaki K, Ishida T, Yano S, Terui Y, Suzuki K Tags: Int J Hematol Source Type: research